A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant

ID Number 12-0730

Principal Investigator(s)
Dan V Iosifescu

Department(s) or Division(s)

Research Entity
Mood and Anxiety Disorders Program - MAP


The purpose of this study is to test whether an experimental drug called SPD489 helps improve the symptoms of depression as an augmentation treatment when added to an antidepressant medication.

One may be able to participate in this study if s/he is between ages of 18 and 65, is currently experiencing symptoms of depression, and is willing to take the study medication along with a prescribed anti-depressant medication. Participation in this research study is expected to last 4-5 months, and includes up to 15 study visits. Compensation for participation will be provided for the volunteer's time.

Contact Information
Gabby Ahle
(212) 241-6349

Recruiting Patients: Yes